Biotech CEOs and CFOs convene in Hanover
The chief executive and financial officers of German biotech companies met on 7 and 8 December in Hanover’s former Pelikan factory, which now serves as a hotel. Despite the rail strike, which was announced at very short notice, some 80 participants attended the annual event to discuss their company’s business models and new developments over the past year in a confidential environment. In his welcoming remarks, Oliver Schacht, Chairman of the Board of BIO Deutschland, stressed how important it is for biotech companies to communicate their business models to policymakers and the public and to highlight the fact that innovations produced by these companies play a key role in value creation – not just in therapy development, but in other areas as well.
In addition to talks by Katja Betts and Maik Lander (PROGEN Biotechnik), Claudia Dierig (Thermo Fisher Scientific), Jens Holstein (BioNTech), Klaus Maleck (ITM), Harpreet Singh (immatics) and Britta Winterberg (Mycolever), there were also short company presentations and start-up pitches.
This year was the 25th edition of the CEO & CFO Meeting. The annual meeting, which brings together the managing directors, CEOs and CFOs of BIO Deutschland’s member companies, takes place in a different location each year.